梯瓦制药Teva Pharmaceutical Industries Limited (TEVA) 2005年年度报告「NYSE」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIESEXCHANGE ACT OF 1934OrANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934For the fiscal year ended December 31,2005OrTRANSI

2、TION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934For the transition period fromtoCommission File number:0-16174TEVA PHARMACEUTICAL INDUSTRIES LIMITED(Exact name of Registrant as specified in its charter)N/AISRAEL(Translation of Registrantsname into English)(Jurisdictio

3、n of incorporationor organization)5 Basel StreetP.O.Box 3190Petach Tikva 49131,Israel(Address of principal executive offices)Securities registered or to be registered pursuant to Section 12(b)of the Act:Title of each className of each exchange on which registeredNoneNoneSecurities registered or to b

4、e registered pursuant to Section 12(g)of the Act:American Depositary Shares(as evidenced by American Depositary Receipts),each representing one Ordinary Share(Title of Class)Securities for which there is a reporting obligation pursuant to Section 15(d)of the Act:0.25%Convertible Senior Debentures Du

5、e 20261.75%Convertible Senior Debentures Due 20265.55%Senior Notes due 20166.15%Senior Notes due 2036and related Guarantees(Title of Class)Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered bythe annual report.646

6、,660,148 Ordinary Shares484,026,847 American Depositary SharesIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No If this report is an annual or transition report,indicate by check mark if the registrant is not required to file